TY  - GEN
AU  - Wardley,Andrew M
AU  - Pivot,Xavier
AU  - Morales-Vasquez,Flavia
AU  - Zetina,Luis M
AU  - de Fátima Dias Gaui,Maria
AU  - Reyes,Douglas Otero
AU  - Jassem,Jacek
AU  - Barton,Claire
AU  - Button,Peter
AU  - Hersberger,Veronica
AU  - Torres,Antonio Antón
TI  - Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer
SN  - 1527-7755
PY  - 2010///0323
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Bone Neoplasms
KW  - drug therapy
KW  - Breast Neoplasms
KW  - Capecitabine
KW  - Deoxycytidine
KW  - Docetaxel
KW  - Feasibility Studies
KW  - Female
KW  - Fluorouracil
KW  - Humans
KW  - In Situ Hybridization, Fluorescence
KW  - International Agencies
KW  - Liver Neoplasms
KW  - Middle Aged
KW  - Neoplasm Staging
KW  - Prognosis
KW  - Receptor, ErbB-2
KW  - genetics
KW  - Soft Tissue Neoplasms
KW  - Survival Rate
KW  - Taxoids
KW  - Trastuzumab
KW  - Treatment Outcome
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.2008.21.6531
ER  -